Browsing: Employers

NEW YORK, Aug 25 (Reuters) – About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, ‌as companies see rising healthcare costs, according to a survey released on Tuesday ‌by the Business Group on Health

Only about one-third of employers cover GLP-1s to treat obesity, leaving many patients facing prohibitively high drug costs on their own

Employers face 11.1% healthcare cost spike but balk at the fix | Insurance Business

L&G’s group protection business is highlighting the benefits of a more proactive approach to absence management, helping employers access support earlier and improve return-to-work outcomes

American employers are approaching an uncomfortable choice: absorb another large increase in healthcare costs or pass more of it on to workers. Mercer projects that employer health-benefit costs will rise 6.7% in 2026, the steepest increase in 15 years, pushing the average cost above $18,500 per employee. Nearly half of large employers expect medical plan…

After years of strong growth, the obesity drug market is now slowing as businesses and health insurers cut back on coverage, signaling a more cautious phase

Access to healthcare is more than a recruiting or retention tool. It’s one of the largest employer investments and a critical factor in workforce stability. Employers are facing a difficult equation: healthcare costs continue to rise while employees expect the same convenience and personalization they experience in nearly every other part of their lives

Psychology says people who love hot air balloons aren’t just adventurous, they may be attracted to awe and freedom

Nearly two-fifths (37 per cent) of Canadian employers cover glucagon-like peptide-1 therapies for both diabetes and weight loss, up from 31 per cent in 2025 and just 17 per cent in 2024, according to a new survey by the International Foundation of Employee Benefit Plans

Cost control, eligibility requirements, and health risks of obesity among key factors shaping employer approach to medication: IFEBP survey